Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
T-cell therapies for T-cell lymphoma.
Toner K, Bollard CM, Dave H. Toner K, et al. Cytotherapy. 2019 Sep;21(9):935-942. doi: 10.1016/j.jcyt.2019.04.058. Epub 2019 Jul 16. Cytotherapy. 2019. PMID: 31320195 Review.
Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma.
Dave H, Terpilowski M, Mai M, Toner K, Grant M, Stanojevic M, Lazarski C, Shibli A, Bien SA, Maglo P, Hoq F, Schore R, Glenn M, Hu B, Hanley PJ, Ambinder R, Bollard CM. Dave H, et al. Among authors: toner k. Blood Adv. 2022 Jan 25;6(2):473-485. doi: 10.1182/bloodadvances.2021005343. Blood Adv. 2022. PMID: 34495306 Free PMC article. Clinical Trial.
Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study.
Wistinghausen B, Toner K, Barkauskas DA, Jerkins LP, Kinoshita H, Chansky P, Pezzella G, Saguilig L, Hayashi RJ, Abhyankar H, Scull B, Karri V, Tanna J, Hanley P, Hermiston ML, Allen CE, Bollard CM. Wistinghausen B, et al. Among authors: toner k. Blood Adv. 2024 Mar 12;8(5):1116-1127. doi: 10.1182/bloodadvances.2023010832. Blood Adv. 2024. PMID: 38163318 Free PMC article.
30 results